EUVIMEDEUVIMED entdecken
Systematische ÜbersichtÜbersichtsarbeitOpen Access · CC BY 4.0

Sodium Butyrate Therapy in Ulcerative Colitis: A Systematic Review of Preclinical and Clinical Evidence

George Ionuț Golea iD, Radu Alexandru Ilieș, Alexandra Caziuc iD, David Andraș iD, Alexandru Ilie-Ene, Radu Seicean, Radu Mircea Neagoe, Ștefana Dăscălescu iD, Luca Simionescu iD, Ștefan Cristian Vesa iD, George Călin Dindelegan iD, Florin Zaharie iD

Medical Sciences · 09.08.2026 · 14 (4) · 469

DOI: 10.3390/medsci14040469 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Medical Sciences, online erschienen am 09.08.2026. Verfasst von George Ionuț Golea und 11 weiteren Autor:innen. Beteiligte Einrichtung: "Iuliu Hațieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania. Hauptthemen laut MEDLINE: Butyric Acid, Colitis, Ulcerative. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Medicine and Pharmacy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Sodium butyrate, a short-chain fatty acid produced by gut microbial fermentation of dietary fiber, has attracted increasing interest as a potential adjunctive therapy for ulcerative colitis (UC) because of its anti-inflammatory, barrier-protective, and immunomodulatory properties. This systematic review aimed to evaluate the current clinical and preclinical evidence regarding the efficacy and mechanisms of sodium butyrate in UC.

Methods

A systematic review was conducted in accordance with the PRISMA 2020 guidelines and registered in PROSPERO (CRD420261437741). PubMed/MEDLINE, Scopus, Web of Science, ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform were searched from February through April 2026. Eligible clinical and experimental studies investigating oral or rectal administration of sodium butyrate in UC or experimental colitis were included. Risk of bias was assessed using RoB 2, ROBINS-I, or the SYRCLE tool according to study design.

Results

Twenty-two studies were included, comprising ten clinical trials, one prospective observational study and eleven preclinical animal studies. In adults diagnosed with UC, oral sodium butyrate, particularly microencapsulated formulations, demonstrated encouraging effects as an adjunct to standard therapy by improving clinical remission rates, quality of life and reducing disease activity and inflammatory biomarkers. Evidence in pediatric inflammatory bowel disease remained inconsistent. Studies evaluating rectal sodium butyrate enemas reported variable clinical efficacy despite evidence of local biological activity. Preclinical studies consistently demonstrated reduced intestinal inflammation, improved epithelial barrier integrity, modulation of oxidative stress, favorable alterations of the gut microbiota, and regulation of several mechanistic pathways identified across individual preclinical studies, including PI3K/AKT/mTOR, WNT/ERK, ERK/STAT3, autophagy and ferroptosis.

Conclusions

Current evidence suggests that sodium butyrate represents a promising adjunctive therapeutic strategy for UC, supported by consistent mechanistic findings and encouraging clinical results, particularly with oral formulations. However, the available clinical evidence remains heterogeneous, and larger, well-designed randomized controlled trials with standardized formulations and treatment protocols are required before its routine clinical implementation can be considered.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Butyric AcidColitis, UlcerativeHumansAnimalsQuality of Life

Stichwörter der Autor:innen

gut microbiotainflammatory bowel diseaseremissionshort-chain fatty acidssodium butyratesystematic reviewulcerative colitis

Substanzen

Butyric Acid

Autor:innen und Institutionen

  • "Iuliu Hațieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
  • Department of General Surgery, First Surgical Clinic, Emergency County Hospital Cluj, 400006 Cluj-Napoca, Romania.
  • Department of Surgery, Surgery Clinic I, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
  • Department of Surgery, "George Emil Palade" University of Medicine, Pharmacy, Science and Technology, 540139 Târgu Mureș, Romania.
  • Department of Medical Oncology, Institute of Oncology "Prof. Dr. Ion Chiricuță", 400015 Cluj-Napoca, Romania.
  • Department of Pharmacology, Toxicology and Clinical Pharmacology, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.

ORCID-Profile: George Ionuț Golea, Alexandra Caziuc, David Andraș, Ștefana Dăscălescu, Luca Simionescu, Ștefan Cristian Vesa, George Călin Dindelegan, Florin Zaharie

Förderung

  • University of Medicine and Pharmacy

Zitieren

APA

Golea, G. I., Ilieș, R. A., Caziuc, A., Andraș, D., Ilie-Ene, A., Seicean, R., Neagoe, R. M., Dăscălescu, Ș., Simionescu, L., Vesa, Ș. C., Dindelegan, G. C., & Zaharie, F. (2026). Sodium Butyrate Therapy in Ulcerative Colitis: A Systematic Review of Preclinical and Clinical Evidence. Medical Sciences, 14(4), 469. https://doi.org/10.3390/medsci14040469

Vancouver

Golea GI, Ilieș RA, Caziuc A, Andraș D, Ilie-Ene A, Seicean R, et al. Sodium Butyrate Therapy in Ulcerative Colitis: A Systematic Review of Preclinical and Clinical Evidence. Medical Sciences. 2026;14(4):469. doi:10.3390/medsci14040469

BibTeX
@article{Golea2026,
  author = {Golea, George Ionuț and Ilieș, Radu Alexandru and Caziuc, Alexandra and Andraș, David and Ilie-Ene, Alexandru and Seicean, Radu and Neagoe, Radu Mircea and Dăscălescu, Ștefana and Simionescu, Luca and Vesa, Ștefan Cristian and Dindelegan, George Călin and Zaharie, Florin},
  title = {Sodium Butyrate Therapy in Ulcerative Colitis: A Systematic Review of Preclinical and Clinical Evidence},
  journal = {Medical Sciences},
  year = {2026},
  volume = {14},
  number = {4},
  pages = {469},
  doi = {10.3390/medsci14040469}
}
Kostenlos starten →